CTVA Stock Movement Summary Corteva shares fell 3% following Q4 2025 earnings results. The company missed fourth-quarter revenue expectations, though it met earnings estimates. Management attributed the revenue miss to seasonal timing shifts, with some deliveries moving from Q4 to Q1 2026. Despite the revenue miss, Corteva provided an optimistic fiscal 2026 outlook, forecasting operating earnings per share above analyst consensus and raising FY 2026 EPS guidance. JPMorgan downgraded Corteva from Overweight to Neutral, citing valuation concerns based on a sum-of-the-parts analysis of the seed and crop chemical businesses. The bank increased its price target to $77.00 from $75.00. Conversely, Royal Bank of Canada raised its price target to $89.00 from $80.00, maintaining an "Outperform" rating. Analyst sentiment remains mixed with a consensus "Moderate Buy" rating.
Read full analysisCTVA Stock Movement Summary Corteva shares fell 3% following Q4 2025 earnings results. The company missed fourth-quarter revenue expectations, though it met earnings estimates. Management attributed the revenue miss to seasonal timing shifts, with some deliveries moving from Q4 to Q1 2026. Despite the revenue miss, Corteva provided an optimistic fiscal 2026 outlook, forecasting operating earnings per share above analyst consensus and raising FY 2026 EPS guidance. JPMorgan downgraded Corteva from Overweight to Neutral, citing valuation concerns based on a sum-of-the-parts analysis of the seed and crop chemical businesses. The bank increased its price target to $77.00 from $75.00. Conversely, Royal Bank of Canada raised its price target to $89.00 from $80.00, maintaining an "Outperform" rating. Analyst sentiment remains mixed with a consensus "Moderate Buy" rating.
Corteva Inc. (CTVA) is a publicly traded company in the Broad Market sector.